Roche Buys Rights To Market Chiasma’s Acromegaly Pill Octreolin
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche is betting Chiasma’s daily oral drug Octreolin will prove a winner for treating orphan disease acromegaly and hopes the Israel-based biotech’s underlying Transient Permeability Enhancer technology can be used to develop other oral drugs that previously were only available by injection.